LONDON, UK / ACCESSWIRE / February 20, 2020 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments of blood diseases, is pleased to announce the following update on its activities.

As previously announced, Hemogenyx's CDX product has the potential to treat Acute Myeloid Leukemia (AML) directly as well as to provide a benign conditioning regimen for blood stem cell replacement therapy. The Company has now carried out extensive work developing treatments for AML and has to date obtained highly encouraging results.

In vivo testing of HEMO-CAR-T indicates anti-cancer activity in a mouse model

As announced on 15 January 2020, Hemogenyx has successfully constructed Chimeric Antigen Receptor (CAR) programmed T cells (HEMO-CAR-T) for the potential treatment of AML. HEMO-CAR was constructed using Hemogenyx's proprietary humanised monoclonal antibody against a target on the surface of AML cells. The Company has now demonstrated in vivo that HEMO-CAR was able to programme human T cells (i.e. convert them into HEMO-CAR-T cells) to identify and destroy human AML derived cells.

Additional engineering may improve safety and versatility of HEMO-CAR-T cells

Following the successful completion of these tests, Hemogenyx is undertaking further engineering of HEMO-CAR to enhance the activity of the technology. The Company is introducing and testing a safety switch within the HEMO-CAR technology that is designed to control the level of activity of HEMO-CAR-T cells. The aim of this safety switch is to turn HEMO-CAR-T cells into a "tunable and controllable drug". The purpose of these efforts is to dramatically improve the safety and potential versatility of HEMO-CAR-T cells for the treatment of AML and/or conditioning of bone marrow transplants, as well as a number of additional potential indications.

Vladislav Sandler, Chief Executive Officer, commented, "We are encouraged by this new data which demonstrates our continuing progress in the development of novel treatments for blood cancers such as AML. The development of HEMO-CAR-T cells expands Hemogenyx's pipeline and advances it into a cutting-edge area of cell-based immune therapy. We are excited to have further developed another product candidate that should, if successful, provide a new and potentially effective treatment for blood cancers for which survival rates are currently very poor."

About AML and CAR-T

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 25% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

CAR-T therapy is a treatment in which a patient's own T cells, a type of immune cell, are modified to recognise and kill the patient's cancer cells. The procedure involves: isolating T cells from the patient; modifying the isolated T cells in a laboratory using a CAR gene construct (which allows the cells to recognise the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Enquiries:

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Non-executive Director

Peter.Redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

lowell@corbomitecomms.com

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals plc

ReleaseID: 577096

LONDON, UK / ACCESSWIRE / February 20, 2020 / Dialog Semiconductor plc (XETRA:DLG), today announced it has signed a definitive agreement to acquire all outstanding shares of Adesto Technologies Corporation ("Adesto") (NASDAQ:IOTS).

Dialog will acquire Adesto for $12.55 per share in cash, or for approximately $500 million enterprise value. The deal will be funded from Dialog's balance sheet.

The transaction is expected to be EPS accretive[1] for Dialog within the first calendar year following close. Dialog expects annual cost synergies of approximately $20 million within the first calendar year of close across the combined company. Dialog also anticipates considerable additional revenue synergies given the complementary nature of the product portfolios and technology. Adesto expects to report FY 2019 revenue of approximately $118 million and continued revenue growth is anticipated over the next few years.

The transaction is subject to certain regulatory approvals and customary closing conditions, including the approval of Adesto's stockholders, and is expected to close in the third quarter of 2020.

The Board of Directors of Adesto has unanimously approved the transaction and recommends that Adesto stockholders vote in favor of the transaction, and directors and executive officers of Adesto have agreed to vote their shares in favor of the transaction.

[1] Financial performance measures are underlying

Information and Explanation of the Issuer to this News:

Forward-Looking Statements

This communication contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. In some cases, you can identify these forward-looking statements by the use of terms such as 'expect,' 'will,' 'continue,' or similar expressions, and variations or negatives of these words, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to: any statements regarding the expected timing of the completion of the transaction and the benefits of the transaction; the ability of Dialog and Adesto to complete the proposed transaction considering the various conditions to the transaction, some of which are outside the parties' control, including those conditions related to regulatory approvals; any other statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These forward-looking statements are inherently uncertain, and are based on information available to each of Dialog and Adesto as of the date hereof and current expectations, forecasts, estimates, and assumptions. A number of important factors and uncertainties could cause actual results or events to differ materially from those described in these forward-looking statements, including without limitation: the failure to satisfy or waive any of the conditions to the consummation of the proposed transaction, including the adoption of the Merger Agreement by Adesto's stockholders and the receipt of certain governmental and regulatory approvals; matters arising in connection with the parties' efforts to comply with and satisfy applicable regulatory approvals and closing conditions relating to the proposed transaction; the risk that the proposed transaction does not close when anticipated or at all; the effects of disruption from the transactions contemplated by the Merger Agreement on Adesto's or Dialog's business and the fact that the announcement and pendency of the transaction may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted against Adesto or Dialog related to the Merger Agreement or the proposed transaction; unexpected costs, charges or expenses resulting from the proposed transaction; the occurrence of a Material Adverse Effect (as defined in the Merger Agreement); and other risks that are described in the reports of Adesto filed with the Securities and Exchange Commission (the 'SEC'), including but not limited to the risks described in Adesto's Annual Report on Form 10-K for its fiscal year ended December 31, 2018, which was filed with the SEC on March 18, 2019, and Adesto's Quarterly Reports on Form 10-Q, and that are otherwise described or updated from time to time in other filings with the SEC. All forward-looking statements attributable to Adesto or Dialog, or persons acting on behalf of either, are expressly qualified in their entirety by this cautionary statement. Further, Adesto and Dialog disclaim any obligation to update the information in this communication or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

Additional Information and Where to Find It

In connection with the proposed acquisition, Adesto will file relevant materials with the SEC, including a preliminary and definitive proxy statement. Promptly after filing the definitive proxy statement, Adesto will mail the definitive proxy statement and a proxy card to the stockholders of Adesto. ADESTO'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY WHEN IT BECOMES AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTION BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Stockholders of Adesto will be able to obtain a free copy of these documents, when they become available, at the website maintained by the SEC at www.sec.gov or free of charge at www.adestotech.com.

Additionally, Adesto and Dialog will file other relevant materials in connection with the proposed acquisition of Adesto by Dialog pursuant to the terms of the Merger Agreement. Adesto, Dialog and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Adesto stockholders in connection with the proposed acquisition. Stockholders of Adesto may obtain more detailed information regarding the names, affiliations and interests of certain of Adesto's executive officers and directors in the solicitation by reading Adesto's most recent Annual Report on Form 10-K, and the proxy statement for Adesto's 2019 annual meeting of stockholders, which was filed with the SEC on April 30, 2019. These documents are available free of charge at the SEC's web site at www.sec.gov or by going to Adesto's Investor Relations Website at www.adestotech.com. Information about Dialog's directors and executive officers is set forth in Dialog's Annual Report and Accounts 2018. You can obtain free copies of this document by accessing Dialog's website at https://www.dialog-semiconductor.com. Information concerning the interests of Adesto's participants in the solicitation, which may, in some cases, be different than those of Adesto's stockholders generally, will be set forth in the definitive proxy statement relating to the proposed transaction when it becomes available.

Contact:

Jose Cano
Director, Investor Relations
jose.cano@diasemi.com
+44(0)1793756961

SOURCE: Dialog Semiconductor Plc. via EQS Newswire

ReleaseID: 577120

Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General Meeting
Nominees bring extensive expertise in the fields of oncology drug discovery, translational science, clinical development, portfolio management, commercial product launch, and capital formation.
Goran Ando, William Lee and Petri Vainio will not stand for re-election after 10 years or more on the Board of Directors

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 20, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced the nomination of three new board members, proposed for election at the 2020 Annual General Meeting on April 29, 2020.

Nominees are as follows:

Sandip Kapadia, Chief Financial Officer (CFO) of Intercept Pharmaceuticals
Michael Vasconcelles, M.D., Chief Medical Officer (CMO) of Flatiron Health
Vito J. Palombella, Ph.D., Chief Scientific Officer (CSO) of Surface Oncology

These nominees have been selected to coincide with the transition of three current members of the board, Goran Ando, William Lee and Petri Vainio. Each of these board members has dutifully served on the Molecular Partners board for 10 years or more and will not stand for re-election. The board's new nominees are veteran U.S. biotech executives and experts in their respective fields, each of which deeply aligns with the current and future growth strategy of Molecular Partners and complements well with the rest of the board's backgrounds and skills. Their collective experience in finance, business development, innovative clinical trial design, and early-stage drug discovery will be critical to Molecular Partners' ongoing growth into a fully integrated oncology company with multiple assets in clinical development.

"I am extremely happy with the nominees proposed for election to the Board of Directors. Each of them possesses an expertise that will be essential as we continue to grow and accelerate our platform of novel therapeutic designs, prepare for our first potential product approval, and carefully evaluate how we invest our capital," said Bill Burns, Chairman of the Board of Directors at Molecular Partners. "As we welcome these new nominees, I wish to extend my thanks to our outgoing board members. For more than ten years, Goran, Bill and Petri have been guiding hands to this company. Each of these individuals remains aligned with the vision of Molecular Partners, and I know that they will continue to support the company as individuals, and investors, well into the future. We wish them all the best in their future endeavors."

Sandip Kapadia is currently CFO of Intercept Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. He has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in Europe and in the United States. Prior to joining Intercept, Sandip held finance leadership positions over 19 years at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands, and the United Kingdom, including CFO of North America at Novartis's generic division, Sandoz. He was previously on the board of Therachon AG and has been serving on the board of directors for Passage Bio since January 2020. Sandip earned his bachelor's degree in business administration and accounting from Montclair State University, an M.B.A from Rutgers Graduate School of Management and is a certified public accountant.

Michael Vasconcelles, M.D., is currently CMO of Flatiron Health, a healthcare technology and services company focused on accelerating cancer research and improving patient care. Prior to Flatiron, Michael served as CMO at Unum Therapeutics Inc., a Cambridge-based oncology biotech focused on developing autologous engineered T cell products for the treatment of cancer. Previously, Michael was accountable for the research and development strategy and execution of the oncology portfolio at both Takeda/Millennium and Genzyme, from discovery through product licensure and post-approval. Michael joined the faculty of the Harvard Medical School in 1996 and is currently a clinical instructor in medicine at Harvard Medical School and a practicing oncologist and associate physician at the Dana-Farber Cancer Institute and Brigham & Women's Hospital in Boston.

Vito J. Palombella, Ph.D., is currently CSO of Surface Oncology, an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment, where he leads the Company's drug discovery and translational research efforts. Vito has over 25 years of scientific leadership and experience advancing first-in-class therapeutic programs. Prior to Surface, he was EVP and CSO at Infinity Pharmaceuticals, where he was responsible for drug discovery and preclinical development. Previously, he was director of molecular biology and protein chemistry at Syntonix Pharmaceuticals, senior director of cell and molecular biology at Millennium Pharmaceuticals, and held a number of positions at LeukoSite and ProScript. Vito was involved in the discovery and development of bortezomib (Velcade®), a proteasome inhibitor, and duvelisib (Copiktra®), a PI3K-d/g inhibitor, both for cancer therapy. Vito earned his bachelor's degree in microbiology from Rutgers University and a master's degree and doctorate degree in viral oncology and immunology from the New York University Medical Center.

Financial Calendar

March 20, 2020

Expected Publication of Annual Report 2019

April 29, 2020

Annual General Meeting

May 7, 2020

Interim Management Statement Q1 2020

August 26, 2020

Publication of Half-year Results 2020 (unaudited)

October 29, 2020

Interim Management Statement Q3 2020

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Seth Lewis, SVP IR, Comms, & Strategy
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617 903 8783

Dr. Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

SOURCE: Molecular Partners AG

ReleaseID: 577034

ST. PETERSBURG, FL / ACCESSWIRE / February 19, 2020 / MMJ International Holdings, the premier medical cannabis research company, announced that it has received approval from Health Canada to ship THC and CBD from Canada.

MMJ International Holdings is developing an oral drug product from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new product for a FDA approved treatment for multiple sclerosis (MS) and Huntington's disease (HD). It also received the US Drug Enforcement Agency's approval to ship the compounds for its clinical trials.

"As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions," said Elio Mariani, PhD, EVP of research & development. "Patients will benefit from cGMP-quality therapies in an accessible and efficient format."

Most recently the FDA awarded MMJ International Holdings ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington's Disease. The drugs, MMJ-001 and MMJ-002 are two of MMJ's lead drugs that the company is confident will bring much-needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington's Disease.

"We firmly believe that our MMJ natural whole plant-derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases," said Duane Boise, CEO of MMJ International Holdings. "We are pleased with Health Canada's approval, and the DEA 's cooperation to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases."

Tim Moynahan the company chairman stated that "Patients in the MMJ International holdings clinical trials will receive gelatin capsules containing THC and CBD daily. MMJ International Holdings has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington's disease." MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking. Tim Moynahan further stated that "Ultimately, there's so much interest in THC and CBD as a treatment modality, so MMJ will be providing the clinical research data necessary to prove patient dosing, safety, and efficacy."

EFFICACY THROUGH CLINICAL TRIALS

With the MMJ's proper formulation of THC and cannabinoids Health Canada and the DEA has afforded MMJ the opportunity to supply its FDA approved clinical trials. MMJ International Holdings FDA studies will begin shortly in Multiple Sclerosis and Huntington's disease. MMJ's is in collaboration with a major US Pharma Solutions Company that develops and produces drug delivery systems. The Pharma Solutions Company offers manufacturing, packaging, storage, and inventory management services for FDA approved drugs, biologics, and consumer health products.

STATE TO STATE MARIJUANA BUSINESSES AT RISK

Recently, President Tump's budget proposal would remove protections for medical marijuana states and block Washington, D.C. from legalizing sales.The reason why the federal Government is opposed to the state to state federally illegal marijuana products is because "There is a significant gap in our understanding of their impact on health," Nora Volkow, Director of NIDA said.

Furthermore, "The recent outbreaks of e-cigarette or vaping product use associated lung injury (EVALI), which has been linked to informally-sourced THC-containing vape products, underscores the critical importance of facilitating researcher access to different product sources."

The budget proposal will allocate about $4 million to an initiative designed to "better regulate THC and cannabis-derived substances in FDA-regulated products. It will also "support regulatory activities, including developing policies and continue to perform its existing regulatory responsibilities including review of drug product applications, inspections, enforcement, and targeted research." Th FDA is committed to protecting the public health and improving regulatory pathways for the lawful marketing of THC and cannabis-derived products within the agency's jurisdiction.

In many cases, product developers make unproven claims to treat serious or life-threatening diseases, and patients may be misled to forgo otherwise effective, available therapy and opt instead for a product that has no proven value or may cause them serious harm."

MMJ International Holdings continues its process of scientific drug development and discovery by FDA protocol development processes, intellectual property portfolio, and DEA regulatory manufacturing guidelines to protect the public health interest.

CONTACT:

Michael Sharp
561-627-9455

SOURCE: MMJ International Holdings

ReleaseID: 577111

BEIJING,CHINA / ACCESSWIRE / February 19, 2020 / Recently, a new insulation material Y-Warm has received the Top 10 Award in ISPO Textrends 2021/22 in the 50th ISPO Munich, which has attracted tremendous attention.

According to CTO Mr. Feipeng Zhang, Y-Warm is a revolutionary insulation material due to its unique combined features. The application of Y-Warm in relevant fields can reduce the carbon emission, be more energy-efficient, more environmentally-friendly and more animal-friendly.

Y-Warm, which consists of environmentally-friendly functional polymer materials and polyester substrates, is a soft and easy-handling material. The thermal conductivity of Y-Warm has been tested with existing methods, as shown in the following table. Obviously, Y-Warm shows an outstanding performance in thermal insulation, with a thermal conductivity at the range of 0.00824 to 0.026 obtained by different testing methods.

The second unique combined feature of Y-Warm is being light, thin, moisture-permeable and quick-drying, which is extremely critical for many application fields. The thickness of Y-Warm is ca. 0.67 mm with the width of 1.5 m. The weight is 43 g/m2.

The next question for Y-Warm with such an excellent united performance will be followed by the safety issues and environmental concerns. CTO Mr. Feipeng Zhong has revealed that the production of Y-Warm is under an aqueous system and the only exhaust is water vapor which can be recycled. The application of Y-Warm in clothing can replace conventional down, therefore reduce the harm to animals and create a more animal-friendly harmonious environment. The volatile organic compound (VOC) of Y-Warm cannot be detected. The antimicrobial test shows that Y-Warm meets the AAA level. To access more tests for safety and environmental issues, please visit http://en.y-warm.com.

Y-Warm can be applied in the temperature range of -50 oC to 150 oC and in the fields such as clothing, outdoors, insulation in constructions/transportation and so on. This product is bringing more opportunities and creativities in clothing and other relevant fields.

About Beijing Y-Warm Technologies Co. Ltd

The project of Y-Warm is launched in 2013 in Beijing. Y-Warm was firstly succeeded in lab R&D in 2017 and the industrialization was achieved in 2019.

To access more information about Y-Warm, please visit http://en.y-warm.com.

Contact:

Y-Warm
Dr. Lei Zhong (in Europe)
Tel: +49 172 7652109

SOURCE: Y-Warm

ReleaseID: 577109